Alessandra Bura1, Valerie Planat-Benard2, Philippe Bourin3, Jean-Sebastien Silvestre4, Fabian Gross5, Jean-Louis Grolleau6, Bertrand Saint-Lebese7, Julie-Anne Peyrafitte2, Sandrine Fleury2, Melanie Gadelorge2, Marion Taurand2, Sophie Dupuis-Coronas2, Bertrand Leobon8, Louis Casteilla9. 1. Service de médecine vasculaire, Pôle cardiovasculaire et métabolique, Centre hospitalo-universitaire de Toulouse, Toulouse, France; Université de Toulouse III, Paul Sabatier, Toulouse, France. 2. CNRS, Université Toulouse III, UPS UMR5273 STROMAlab, Toulouse, France; EFS (Etablissement Français du Sang), STROMAlab, Toulouse, France; Inserm U1031 STROMAlab, Toulouse, France; Université Toulouse III, UPS UMR5273 STROMAlab, Toulouse, France. 3. EFS (Etablissement Français du Sang), STROMAlab, Toulouse, France; CSA21, 7 chemin des silos, Toulouse, France. 4. INSERM UMRS 970, Paris Cardiovascular Research Center, Université Paris Descartes, Sorbonne Paris cité, Paris, France. 5. Centre d'Investigation Clinique de Biothérapies de Toulouse, Toulouse cedex 9, France; Direction de la Recherche Médicale et Innovation (DRMI) du CHU de Toulouse, Toulouse cedex 9, France. 6. Université de Toulouse III, Paul Sabatier, Toulouse, France; Service de chirurgie plastique, reconstructrice et esthétique, Centre hospitalo-universitaire de Toulouse, Toulouse, France. 7. Service de chirurgie vasculaire, Pôle cardiovasculaire et métabolique, Centre hospitalo-universitaire de Toulouse, Toulouse, France. 8. Université de Toulouse III, Paul Sabatier, Toulouse, France; Service de chirurgie cardiovasculaire, Pôle cardiovasculaire et métabolique, Centre hospitalo-universitaire de Toulouse, Toulouse, France. 9. CNRS, Université Toulouse III, UPS UMR5273 STROMAlab, Toulouse, France; EFS (Etablissement Français du Sang), STROMAlab, Toulouse, France; Inserm U1031 STROMAlab, Toulouse, France; Université Toulouse III, UPS UMR5273 STROMAlab, Toulouse, France. Electronic address: louis.casteilla@inserm.fr.
Abstract
BACKGROUND AIMS: Non-revascularizable critical limb ischemia (CLI) is the most severe stage of peripheral arterial disease, with no therapeutic option. Extensive preclinical studies have demonstrated that adipose-derived stroma cell (ASC) transplantation strongly improves revascularization and tissue perfusion in ischemic limbs. This study, named ACellDREAM, is the first phase I trial to evaluate the feasibility and safety of intramuscular injections of autologous ASC in non-revascularizable CLI patients. METHODS: Seven patients were consecutively enrolled, on the basis of the following criteria: (i) lower-limb rest pain or ulcer; (ii) ankle systolic oxygen pressure <50 or 70 mm Hg for non-diabetic and diabetic patients, respectively, or first-toe systolic oxygen pressure <30 mm Hg or 50 mm Hg for non-diabetic and diabetic patients, respectively; (iii) not suitable for revascularization. ASCs from abdominal fat were grown for 2 weeks and were then characterized. RESULTS: More than 200 million cells were obtained, with almost total homogeneity and no karyotype abnormality. The expressions of stemness markers Oct4 and Nanog were very low, whereas expression of telomerase was undetectable in human ASCs compared with human embryonic stem cells. ASCs (10(8)) were then intramuscularly injected into the ischemic leg of patients, with no complication, as judged by an independent committee. Trans-cutaneous oxygen pressure tended to increase in most patients. Ulcer evolution and wound healing showed improvement. CONCLUSIONS: These data demonstrate the feasibility and safety of autologous ASC transplantation in patients with objectively proven CLI not suitable for revascularization. The improved wound healing also supports a putative functional efficiency.
BACKGROUND AIMS: Non-revascularizable critical limb ischemia (CLI) is the most severe stage of peripheral arterial disease, with no therapeutic option. Extensive preclinical studies have demonstrated that adipose-derived stroma cell (ASC) transplantation strongly improves revascularization and tissue perfusion in ischemic limbs. This study, named ACellDREAM, is the first phase I trial to evaluate the feasibility and safety of intramuscular injections of autologous ASC in non-revascularizable CLI patients. METHODS: Seven patients were consecutively enrolled, on the basis of the following criteria: (i) lower-limb rest pain or ulcer; (ii) ankle systolic oxygen pressure <50 or 70 mm Hg for non-diabetic and diabeticpatients, respectively, or first-toe systolic oxygen pressure <30 mm Hg or 50 mm Hg for non-diabetic and diabeticpatients, respectively; (iii) not suitable for revascularization. ASCs from abdominal fat were grown for 2 weeks and were then characterized. RESULTS: More than 200 million cells were obtained, with almost total homogeneity and no karyotype abnormality. The expressions of stemness markers Oct4 and Nanog were very low, whereas expression of telomerase was undetectable in human ASCs compared with human embryonic stem cells. ASCs (10(8)) were then intramuscularly injected into the ischemic leg of patients, with no complication, as judged by an independent committee. Trans-cutaneous oxygen pressure tended to increase in most patients. Ulcer evolution and wound healing showed improvement. CONCLUSIONS: These data demonstrate the feasibility and safety of autologous ASC transplantation in patients with objectively proven CLI not suitable for revascularization. The improved wound healing also supports a putative functional efficiency.
Authors: Trivia P Frazier; Annie Bowles; Stephen Lee; Rosalyn Abbott; Hugh A Tucker; David Kaplan; Mei Wang; Amy Strong; Quincy Brown; Jibao He; Bruce A Bunnell; Jeffrey M Gimble Journal: Stem Cells Date: 2016-03-09 Impact factor: 6.277
Authors: Amy L Strong; Annie C Bowles; Connor P MacCrimmon; Trivia P Frazier; Stephen J Lee; Xiying Wu; Adam J Katz; Barbara Gawronska-Kozak; Bruce A Bunnell; Jeffrey M Gimble Journal: Stem Cells Transl Med Date: 2015-04-21 Impact factor: 6.940